文献速递妇科母胎医学

术前阴道内雌激素对有症状盆腔器官脱垂的绝经后女性盆底功能障碍症状的影响

Effects of preoperative intravaginal estrogen on pelvic floor disorder symptoms in postmenopausal women with pelvic organ prolapse.
PubMed 文献 · Am J Obstet Gynecol · 2023-05-25

本研究为「使用雌激素最小化阴道脱垂复发研究」随机双盲试验的计划性辅助分析,纳入199例≥2期顶端和/或前壁脱垂、拟行经阴道自体组织顶端修补的绝经后女性,比较阴道内结合雌激素霜与安慰剂对盆底症状的影响。结果显示两组在压力性尿失禁、急迫性尿失禁、尿频、性功能及性交困难方面无显著差异,仅依从者客观萎缩征象改善更明显,结论尚不确定,需进一步研究。

要点

  • 阴道内雌激素组与安慰剂组在压力性尿失禁改善率(50% vs 43%,P=.78)等方面无显著差异。
  • 依从者中阴道内雌激素组客观萎缩征象改善优于安慰剂组(+1.54 vs +0.69,P=.01)。
  • 术前7周阴道内雌激素对泌尿、性功能及萎缩相关症状的改善结论尚不确定,需进一步研究。

核心结论

  • 尽管依从者阴道上皮出现与雌激素化增加一致的客观改变,但术前7周阴道内雌激素霜是否改善泌尿功能、性功能、性交困难症状及其他常归因于萎缩的症状,结论尚不确定,需进一步研究。

研究设计与样本

  • 此为「使用雌激素最小化阴道脱垂复发研究」随机双盲试验的计划性辅助分析,纳入≥2期顶端和/或前壁脱垂、拟行经阴道自体组织顶端修补的参与者,来自3个美国中心。
  • 干预为1 g结合雌激素阴道霜(0.625 mg/g)或相同安慰剂(1:1),每晚插入2周,之后每周2次,术前总计≥5周,术后继续每周2次持续1年。
  • 共199例参与者随机化(平均年龄65岁)并提供基线数据,其中191例有术前数据;按意向治疗和符合方案(即依从≥50%预期阴道霜使用,通过管重量客观评估)分析。

主要发现

  • 基线至术前访视中位时间7周内,泌尿困扰量表-6总分变化极小;基线压力性尿失禁至少中度困扰者中,雌激素组32例中16例(50%)改善,安慰剂组21例中9例(43%)改善(P=.78)。
  • 急迫性尿失禁改善率雌激素组43%、安慰剂组31%(P=.41);尿频改善率雌激素组41%、安慰剂组26%(P=.18)。
  • 性活跃女性中盆腔器官脱垂/尿失禁性功能问卷-IUGA修订版评分变化极小;术前评估时性交困难率雌激素组42%、安慰剂组48%(P=.49)。
  • 基线有症状且依从研究霜者中,最困扰萎缩症状最高分在雌激素组略有改善(校正平均差-0.33分,95%CI -0.98至0.31),但无统计学显著性(P=.19)。
  • 依从者中,雌激素组客观萎缩征象改善优于安慰剂组(+1.54 vs +0.69;平均差0.85,95%CI 0.05-1.65;P=.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出,术前7周阴道内雌激素是否改善泌尿功能、性功能、性交困难症状及其他常归因于萎缩的症状,结论尚不确定,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Menopause and the decline in systemic estrogen are associated with the development of pelvic floor disorders, such as prolapse, urinary incontinence, overactive bladder, and vulvovaginal atrophy symptoms. Past evidence suggests that postmenopausal women with symptomatic prolapse gain benefit from the preoperative application of intravaginal estrogen, but it is unknown whether they would experience improvement in other pelvic floor symptoms when treated with intravaginal estrogen. OBJECTIVE: This study aimed to determine the effects of intravaginal estrogen (compared with placebo) on stress and urgency urinary incontinence, urinary frequency, sexual function and dyspareunia, and vaginal atrophy symptoms and signs in postmenopausal women with symptomatic prolapse. STUDY DESIGN: This was a planned ancillary analysis of a randomized, double-blind trial, "Investigation to Minimize Prolapse Recurrence Of the Vagina using Estrogen," which included participants with ≥stage 2 apical and/or anterior prolapse scheduled for transvaginal native tissue apical repair at 3 US sites. The intervention was 1 g conjugated estrogen intravaginal cream (0.625 mg/g) or identical placebo (1:1), inserted nightly for 2 weeks and then twice weekly for ≥5 weeks total before surgery and continued twice weekly for 1 year postoperatively. For this analysis, question responses were compared from participants' baseline and preoperative visits: lower urinary tract symptoms (Urogenital Distress Inventory-6 Questionnaire); sexual health questions, including dyspareunia (Pelvic Organ Prolapse/Incontinence Sexual Function Questionnaire-IUGA-Revised); and atrophy-related symptoms (dryness, soreness, dyspareunia, discharge, and itching; each scored 1-4, 4 being quite a bit bothersome). Masked examiners assessed vaginal color, dryness, and petechiae (each scored 1-3, total range 3-9, with 9 being the most estrogenized appearing). Data were analyzed by intent to treat and "per protocol" (ie, those adherent with ≥50% of expected intravaginal cream use, per objective tube before and after weights). RESULTS: Of 199 participants randomized (mean age of 65 years) and contributing baseline data, 191 had preoperative data. The characteristics were similar between groups. Total Urogenital Distress Inventory-6 Questionnaire scores showed minimal change during this median time of 7 weeks between baseline and preoperative visits, but for those with at least moderately bothersome baseline stress urinary incontinence (32 in the estrogen group and 21 in the placebo group), 16 (50%) in the estrogen group and 9 (43%) in the placebo group showed improvement (P=.78). In addition, 43% of participants in the estrogen group and 31% of participants in the placebo group showed improvement in urgency urinary incontinence (P=.41), and 41% of participants in the estrogen group and 26% of participants in the placebo group showed improvement in urinary frequency (P=.18). There was minimal change in the Pelvic Organ Prolapse/Incontinence Sexual Function Questionnaire-IUGA-Revised scores among sexually active women; dyspareunia rates did not differ between intravaginal estrogen and placebo at the preoperative assessment: 42% and 48%, respectively (P=.49). The maximum score for most bothersome atrophy symptom (among those with baseline symptoms and adherent to study cream) improved slightly more with intravaginal estrogen (adjusted mean difference, -0.33 points; 95% confidence interval, -0.98 to 0.31), but this was not statistically significant (P=.19). However, on examination, among adherent participants, objective signs of atrophy were more improved with intravaginal estrogen treatment (+1.54 vs +0.69; mean difference, 0.85; 95% confidence interval, 0.05-1.65; P=.01). CONCLUSION: Despite objective changes in the vaginal epithelium consistent with increased estrogenization among drug-adherent participants, the results were inconclusive regarding whether 7 weeks of preoperative intravaginal estrogen cream in postmenopausal women with symptomatic pelvic organ prolapse was associated with improved urinary function, sexual function, dyspareunia symptoms, and other symptoms commonly attributed to atrophy. Additional study is needed.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rahn DD, Richter HE, Sung VW, et al. Effects of preoperative intravaginal estrogen on pelvic floor disorder symptoms in postmenopausal women with pelvic organ prolapse. Am J Obstet Gynecol. 2023. PMID: 37244454. doi:10.1016/j.ajog.2023.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。